These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...

Janux Therapeutics (NASDAQ:JANX – Get Free Report) is expected to announce its earnings results before the market opens on ...

We recently compiled a list of the 10 Stocks With At Least $30 Million In Insider Spending Recently. In this article, we are ...

Meanwhile, Janux also reported early data with its second TRACTr candidate, EGFR-targeting JANX008 in a basket study involving patients with various solid tumours, including colorectal ...

Janux’s TRACTr and TRACIr Pipeline Janux’s first clinical candidate, JANX007, is a TRACTr that targets prostate-specific membrane antigen (PSMA) and is being investigated in a Phase 1 clinical ...

Janux Therapeutics, Inc. ( ($JANX) ) has released its Q4 earnings. Here is a breakdown of the information Janux Therapeutics, Inc. presented to ...

Janux Therapeutics (NASDAQ:JANX – Get Free Report)‘s stock had its “buy” rating restated by investment analysts at HC ...

Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor ...

Tumor Activated T-cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) are two unique platforms that the company has created. Janux Therapeutics, Inc. (NASDAQ:JANX) develops safe ...

Tumor Activated T-cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) are two unique platforms that the company has created. Janux Therapeutics, Inc. (NASDAQ:JANX) develops safe ...

Janux as we displayed the potential power of our TRACTr platform in the clinic. We believe the data recently presented from JANX007 demonstrated substantial clinical activity in late line mCRPC ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...